Vijaya Diagnostic Centre Limited reported a 22.8% year-on-year increase in consolidated revenue from operations to ₹2,310 million for the quarter ended June 30, 2026, driven by strong volume growth and the commissioning of advanced diagnostic hubs in Hyderabad and Bengaluru. Profit after tax (PAT) surged 38.6% to ₹531 million, while earnings before interest, tax, depreciation, and amortization (EBITDA) rose 34.0% to ₹985 million, reflecting improved operating leverage. The results, disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlight the company's ability to scale organically in core geographies while expanding its footprint in newer markets.

The financial performance was underpinned by a 16.5% increase in total tests performed to 4.59 million and a 12.7% rise in footfalls to 1.24 million. Average realization per test grew 5.5% to ₹503, indicating that growth is supported by both volume expansion and moderate price realization improvements. The company's integrated business model, characterized by a high B2C concentration, continues to drive industry-leading margins and cash generation.

Financial Performance

The key financial metrics for Q1FY27 demonstrate consistent growth across top-line and bottom-line parameters compared to the corresponding period in FY26. The EBITDA margin expanded by 357 basis points to 42.67%, while the PAT margin widened to 23.0%.

Operational Highlights

Operational metrics reflect increased patient engagement and efficient utilization of infrastructure. The number of tests per footfall rose to 3.70 from 3.58 in Q1FY26, suggesting deeper penetration of diagnostic services per patient visit. The wellness segment continued to show sustained momentum, with its share contributing 14.8% to the revenue mix, up from 14.2% in the previous year.

Strategic Expansion and Technology

Vijaya Diagnostic Centre Limited inaugurated several new facilities in Q1FY27, reinforcing its densification strategy. Key developments include:

• Bengaluru: Launched a state-of-the-art flagship hub in JP Nagar in July 2026, featuring a digital PET-CT with an in-built cardiac CT and a wide-bore 75cm 3T Omega MRI, noted as the first of its kind in Karnataka.
• Hyderabad: Opened a hub centre in Gachibowli in April 2026, equipped with a 160-slice cardiac CT, and two spokes in Ramanthapur and Chintalmet in June 2026.
• Andhra Pradesh & Pune: Commissioned four additional spokes across Hyderabad, Andhra Pradesh, and Pune during the quarter.

What the Numbers Show

The divergence between revenue growth (22.8%) and EBITDA growth (34.0%) indicates significant operating leverage as the company scales. With the average realization per test rising alongside volume growth, the company is successfully balancing accessibility with premium service offerings. The expansion into high-end imaging technologies, such as the wide-bore MRI in Bengaluru, positions the company to capture higher-margin radiology revenues, further supporting margin expansion trends observed in the quarter.

Vijaya Diagnostic Centre Limited reported a 36.1% year-on-year increase in consolidated net profit to ₹531.01 lakh for the first quarter ended June 30, 2026, driven by robust growth in revenue from operations. Consolidated revenue rose 22.8% to ₹2,309.82 lakh from ₹1,880.53 lakh in the corresponding period of the previous year, reflecting strong demand in its diagnostic services segment. The Board of Directors, meeting on August 06, 2026, approved the unaudited standalone and consolidated financial results and recommended a dividend of Re. 2 per equity share, representing a 200% payout for the financial year 2025-26, pending approval at the ensuing Annual General Meeting.

The filing was submitted pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors B S R and Co conducted a limited review of the interim financial information and issued an unmodified report. The results were prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. Management highlighted that the comparative figures have been restated to reflect the amalgamation of Medinova Diagnostic Services Limited, approved by the National Company Law Tribunal (NCLT) on October 13, 2025, ensuring consistent presentation across reporting periods.

Financial Performance Highlights

Consolidated profit before tax increased to ₹709.45 lakh from ₹522.07 lakh in Q1FY25, aided by operational efficiencies despite a rise in total expenses to ₹1,685.68 lakh. Standalone net profit also grew significantly, reaching ₹531.48 lakh compared to ₹390.50 lakh in the prior year period. Earnings per equity share (basic) stood at ₹5.16 on a consolidated basis and ₹5.17 on a standalone basis, up from ₹3.76 and ₹3.80 respectively in the same quarter last year.

Operational Updates and Corporate Actions

During the quarter, the company granted 179,500 employee stock options to eligible employees under the 'Employee Stock Option Plan 2018', as approved by the Nomination and Remuneration Committee on May 07, 2026. This move aligns with the company's strategy to retain key talent amidst expansion. Additionally, the Board had previously approved the acquisition of Medinova Millennium MRI Services LLP via a slump sale, accounted for using the pooling of interest method under Ind AS 103. This transaction has been integrated into the financial statements, with assets and liabilities recorded at their existing carrying amounts.

What the Numbers Show

The divergence between revenue growth (22.8%) and expense growth (18.0%) indicates improving operating leverage for Vijaya Diagnostic Centre Limited. While employee benefits and finance costs rose due to business expansion and inflationary pressures, the company managed to control cost of materials consumed relative to revenue. The significant jump in net profit, outpacing revenue growth, suggests that fixed costs are being spread over a larger revenue base, enhancing overall profitability margins. The proposed 200% dividend further signals management's confidence in cash flow generation and commitment to shareholder returns.